Welcome to our dedicated page for Omnicell Com SEC filings (Ticker: OMCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Omnicell, Inc. (NASDAQ: OMCL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, along with AI-powered tools to help interpret complex documents. As a publicly traded healthcare technology company focused on intelligent medication management, Omnicell files a range of reports with the U.S. Securities and Exchange Commission that describe its financial condition, risks, governance, and material events.
Investors and researchers can use this page to review Omnicell’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss topics such as revenues from connected devices, technical services, SaaS and Expert Services, and consumables, as well as the company’s strategy to transform into a digitally enabled medication management technology company. Current reports on Form 8-K provide timely updates on matters including quarterly financial results, amendments to bylaws, and the appointment of executive officers.
For users interested in governance and corporate structure, filings detail actions like the adoption of amended and restated bylaws that refine stockholder nomination procedures, address proxy rule requirements, and clarify jurisdictional provisions. Risk factor discussions in Omnicell’s periodic reports outline considerations related to economic conditions, demand for medication management solutions, regulatory and legal obligations, cybersecurity, supply chain, and competition.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the implications of Omnicell’s 10-Ks, 10-Qs, and 8-Ks without reading every page. Real-time updates from EDGAR, combined with structured access to historical filings, allow investors to follow how OMCL’s disclosures evolve over time and to connect regulatory information with the company’s broader narrative in medication management technology.
Omnicell executive Corey J. Manley, EVP & Chief Legal/Admin Officer, sold 6,106 shares of Omnicell common stock on January 8, 2026. The sale was executed at an exact price of $49.90 per share under a pre-arranged Rule 10b5-1 trading plan adopted on June 13, 2025, which is designed to allow insiders to sell stock according to preset instructions. After this transaction, Manley beneficially owned 91,674 shares of Omnicell common stock directly.
Omnicell insider Corey Manley has filed a Form 144 notice to sell up to 6,106 shares of Omnicell common stock through Fidelity Brokerage Services on NASDAQ, with an indicated aggregate market value of $304,689.40. The planned sale involves common shares, while Omnicell had 44,876,522 shares of common stock outstanding; this is a baseline figure, not the amount being sold.
The shares to be sold were acquired mainly through restricted stock vesting and an employee stock purchase plan between December 2023 and March 2025, including grants of 3,590 shares on March 1, 2025 and 1,370 shares on August 15, 2024. Over the prior three months before this notice, Manley sold 3,473, 6,106, and 278 shares of Omnicell common stock in separate transactions, receiving gross proceeds of $121,207.70, $243,629.40, and $12,037.40, respectively.
Omnicell, Inc.'s Executive Vice President and Chief Legal/Administrative Officer reported routine share movements. On December 15, 2025, 224 shares of common stock were withheld to cover taxes due on the vesting of restricted stock units. On December 16, 2025, the executive sold 278 shares of Omnicell common stock at an exact price of $43.30 per share.
The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on June 13, 2025, which is designed to allow insiders to sell shares according to a preset schedule. After these transactions, the executive beneficially owned 97,780 shares of Omnicell common stock, all held directly.
Omnicell, Inc. reported an insider equity transaction by its Chairman, President and CEO and director, Randall Lipps. On 12/15/2025, the company withheld 1,147 shares of common stock at $43.27 per share to cover taxes due upon the vesting of restricted stock units, which is a non-open-market transaction. After this tax withholding, Mr. Lipps beneficially owned 385,501 shares of Omnicell common stock directly, plus 355,861 shares held in a trust with his wife and 8,051 shares held in trust for the benefit of his children.
Omnicell, Inc. (OMCL) executive Brian H. Nutt, the VP and Chief Accounting Officer, reported a small insider transaction on Form 4. The filing shows that 226 shares of common stock were withheld to cover taxes due in connection with the vesting of restricted stock units at a price of $35.12 per share. After this tax withholding, Nutt directly owns 17,342 shares of Omnicell common stock. This is an administrative equity event tied to compensation rather than an open‑market buy or sell.
Omnicell, Inc. reported an insider share disposition by its Chairman, President and CEO, Randall A. Lipps. On 11/15/2025, Lipps disposed of 8,437 shares of Omnicell common stock at a price of $35.12 per share, coded as an "F" transaction, which indicates shares were withheld to cover taxes related to vesting restricted stock units. Following this transaction, he directly owned 386,648 shares. He also held 355,861 shares in a trust with his wife and 8,051 shares in a trust for the benefit of his children.
Omnicell, Inc. executive reports routine share withholding for taxes. The company’s EVP and Chief Operating Officer reported the disposition of 4,095 shares of Omnicell common stock on 11/15/2025 at a price of $35.12 per share, coded as an "F" transaction, which indicates shares were withheld to cover taxes due on vesting of restricted stock units.
After this tax withholding, the executive beneficially owns 87,193 shares of Omnicell common stock. This balance includes an adjustment for 359 shares purchased under Omnicell’s Employee Stock Purchase Plan on 8/15/2025, as noted in the footnotes.
Omnicell, Inc. (OMCL) reported an equity award to its Executive Vice President & Chief Financial Officer, H. Baird Radford III, on a Form 4. On 11/15/2025, he received 32,932 shares of Omnicell common stock in the form of restricted stock units granted under the company’s equity incentive plan at a stated price of $0 per share, reflecting a stock-based award rather than a cash purchase. After this grant, he beneficially owns 32,932 shares directly. The award vests over time: 25% of the shares are scheduled to vest on November 15, 2026, and the remaining 75% vest in equal quarterly installments over three years on 2/15, 5/15, 8/15, and 11/15, aligning his compensation with longer-term company performance.
Omnicell, Inc. (OMCL) reported an insider equity transaction involving an executive advisor. On 11/15/2025, 7,368 shares of common stock were withheld at a price of $35.12 per share to cover taxes due on the vesting of restricted stock units. After this tax withholding, the reporting person beneficially owned 117,808 shares of Omnicell common stock directly. The filing notes that the transaction may have been executed under a Rule 10b5-1 trading plan.
Omnicell, Inc. executive reports routine stock transactions. The EVP and Chief Legal/Administrative Officer reported two transactions in Omnicell common stock. On 11/15/2025, 2,792 shares were withheld to cover taxes due on vesting of restricted stock units at a price of $35.12 per share, leaving 107,861 shares beneficially owned. On 11/17/2025, the executive sold 3,473 shares at an exact price of $34.90 per share under a pre-arranged Rule 10b5-1 trading plan adopted on June 13, 2025, resulting in 104,388 shares beneficially owned after the sale. The filing is made by one reporting person.